Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maria Tampaki has a total of 97 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Sa2145 THE PRESENCE OF CIRRHOSIS DOES NOT AFFECT RESPONSE RATES OF BULEVIRTIDE THERAPY IN PATIENTS WITH CHRONIC HEPATITIS DELTA

    by Alexandros Pelekanos, Hariklia Kranidioti, Iliana Mani, Eleni Geladari, Nikolaos Tsiamperas, Ourania Charalampous, Georgios Kontos, Maria Tampaki, Nikolaos Papadopoulos, Vasileios Papadimitropoulos, et al.

  • Sa2145 THE PRESENCE OF CIRRHOSIS DOES NOT AFFECT RESPONSE RATES OF BULEVIRTIDE THERAPY IN PATIENTS WITH CHRONIC HEPATITIS DELTA

    by Alexandros Pelekanos, Hariklia Kranidioti, Iliana Mani, Eleni Geladari, Nikolaos Tsiamperas, Ourania Charalampous, Georgios Kontos, Maria Tampaki, Nikolaos Papadopoulos, Vasileios Papadimitropoulos, et al.

  • Open Access

    Distinct Laboratory and Clinical Features of Metabolic and Alcohol-Related Liver Disease (MetALD): A Systematic Review and Meta-Analysis

    by Maria Tampaki, Vasileios Lekakis, Christos Chologkitas, Stergios Α. Polyzos, Evangelos Cholongitas

    Purpose of review: We aimed to perform a systematic review and meta-analysis of observational studies, primarily to compare laboratory findings, including liver function tests, and metabolic parameters, between patients with Metabolic and alcohol-related/associated liver disease (MetALD) and those with metabolic dysfunction-associated steatotic liver disease (MASLD) or alcohol-related liver disease (ALD). Recent findings: MetALD is a newly recognized subtype of steatotic liver disease (SLD) characterized by the synergistic impact of metabolic dysfunction and alcohol consumption. Data on its clinical and laboratory profile remain limited. Summary: Thirty-three studies including 7,504,674 individuals were analyzed. Compared to MASLD, MetALD was associated with higher aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transferase (GGT), higher triglycerides (TG) and high density lipoprotein-cholesterol (HDL-C), lower low density lipoprotein-cholesterol (LDL-C), and higher systolic and diastolic blood pressure, but lower body mass index (BMI) and hemoglobin A1c (HbA1c). Compared to ALD, MetALD showed lower liver enzymes, while most metabolic parameters were similar. Conclusions: MetALD has distinct laboratory and metabolic features compared to MASLD, while differences with ALD are less pronounced. These findings favor MetALD as a distinct entity warranting further, more focused research.


  • Open Access

    Over-the-Scope Endoscopic Clip as Rescue Therapy for Massive Esophageal Variceal Bleeding

    by Andreas Koutsoumpas, Maria Tampaki, Theodoros Alexopoulos, Vasileios Lekakis, Antonia Neonaki, Konstantinos Papaxoinis, Georgios Papatheodoridis


  • Open Access

    Management of Hepatocellular Carcinoma in Decompensated Cirrhotic Patients: A Comprehensive Overview

    by Maria Tampaki, George V. Papatheodoridis, Evangelos Cholongitas

    Primary liver cancer is the sixth most common cancer and the fourth leading cause of cancer-related death. Hepatocellular carcinoma (HCC) accounts for 75% of primary liver cancer cases, mostly on the basis of cirrhosis. However, the data and therapeutic options for the treatment of HCC in patients with decompensated cirrhosis are rather limited. This patient category is often considered to be in a terminal stage without the possibility of a specific treatment except liver transplantation, which is restricted by several criteria and liver donor shortages. Systemic treatments may provide a solution for patients with Child Pugh class B or C since they are less invasive. Although most of the existing trials have excluded patients with decompensated cirrhosis, there are increasing data from real-life settings that show acceptable tolerability and satisfying efficacy in terms of response. The data on the administration of locoregional treatments in such patients are also limited, but the overall survival seems to be potentially prolonged when patients are carefully selected, and close adverse event monitoring is applied. The aim of this review is to analyze the existing data regarding the administration of treatments in decompensated patients with HCC, evaluate the effect of therapy on overall survival and highlight the potential risks in terms of tolerability.


  • Open Access

    Cellular, Molecular and Proteomic Characteristics of Early Hepatocellular Carcinoma

    by Athanasios Armakolas, Vasiliki Dimopoulou, Adrianos Nezos, George Stamatakis, Martina Samiotaki, George Panayotou, Maria Tampaki, Martha Stathaki, Spyridon Dourakis, John Koskinas

    Hepatocellular carcinoma (HCC) accounts for the majority of primary liver cancers. Early detection/diagnosis is vital for the prognosis of HCC, whereas diagnosis at late stages is associated with very low survival rate. Early diagnosis is based on 6-month surveillance of the patient and the use of at least two imaging modalities. The aim of this study was to investigate diagnostic markers for the detection of early HCC based on proteome analysis, microRNAs (miRNAs) and circulating tumor cells (CTCs) in the blood of patients with cirrhosis or early or advanced HCC. We studied 89 patients with HCC, of whom 33 had early HCC and 28 were cirrhotic. CTCs were detected by real-time quantitative reverse transcription PCR and immunofluorescence using the markers epithelial cell adhesion molecule (EPCAM), vimentin, alpha fetoprotein (aFP) and surface major vault protein (sMVP). Expression of the five most common HCC-involved miRNAs (miR-122, miR-200a, miR-200b, miR-221, miR-222) was examined in serum using quantitative real time PCR (qRT-PCR). Finally, patient serum was analyzed via whole proteome analysis (LC/MS). Of 53 patients with advanced HCC, 27 (51%) had detectable CTCs. Among these, 10/27 (37%) presented evidence of mesenchymal or intermediate stage cells (vimentin and/or sMVP positive). Moreover, 5/17 (29%) patients with early HCC and 2/28 (7%) cirrhotic patients had detectable CTCs. Patients with early or advanced HCC exhibited a significant increase in miR-200b when compared to cirrhotic patients. Our proteome analysis indicated that early HCC patients present a significant upregulation of APOA2, APOC3 proteins when compared to cirrhotic patients. When taken in combination, this covers the 100% of the patients with early HCC. miR-200b, APOA2 and APOC3 proteins are sensitive markers and can be potentially useful in combination for the early diagnosis of HCC.


  • Risk of HBV reactivation during therapies for HCC: A systematic review

    by Margarita Papatheodoridi, Maria Tampaki, Anna S. Lok, George V. Papatheodoridis

    Background and Aims: Treatment for HCC has evolved rapidly, but the risk of HBV reactivation to new therapies is unclear. We systematically reviewed data on HBV reactivation in patients receiving HCC therapy in relation to use of HBV antiviral prophylaxis. Approach and Results: A literature search was performed to identify all published studies including HBsAg‐positive patients with HCC providing data on HBV reactivation. Forty‐one studies with 10,223 patients, all from Asia, were included. The pooled HBV reactivation rate was 5% in patients receiving no specific HCC therapy and was higher in patients undergoing surgical resection (16%), transarterial chemoembolization (19%), or radiotherapy (14%) and intermediate in patients treated with local ablation therapy (7%) or systemic agents (7%). HBV reactivation rates were higher in those without compared to those with HBV prophylaxis (ablation, 9% versus 0%; resection, 20% versus 3%; chemoembolization, 23% versus 1%; external radiotherapy alone, 18% versus 0%; systemic therapy, 9% versus 3%). HBV‐related biochemical reactivation rates varied between 6%–11% and 2% in patients receiving HCC therapies with high and intermediate HBV reactivation risk, respectively. Liver decompensation and death were rarely reported (0%–3%) and only in patients receiving HCC treatment with high HBV reactivation risk. Conclusions: HBsAg‐positive patients with HCC are at high or intermediate risk of HBV reactivation depending on the type of HCC therapy. Nucleos(t)ide analogue prophylaxis reduces the risk of HBV reactivation, practically eliminates the risk of hepatitis flare, and should be administered regardless of HCC treatment.


  • Wilson disease: 30-year data on epidemiology, clinical presentation, treatment modalities and disease outcomes from two tertiary Greek centers

    by Maria Tampaki, Nikolaos K. Gatselis, Spyridon Savvanis, Emmanouil Koullias, Asterios Saitis, Stella Gabeta, Melanie Deutsch, Emmanouil Manesis, Georgios N. Dalekos, John Koskinas

    Objective: Wilson disease is a rare genetic disorder of copper metabolism with a wide range of clinical presentations. The aim of this study is to describe the 30-year clinical experience in the management of Wilson disease patients followed at two Greek referral centers. Methods: A retrospective chart review was performed to identify past and present Wilson disease patients diagnosed during the last 30 years. Results: Sixty-three patients were included. The median age of diagnosis was 19 (3–59) years, while nine (14%) patients were older than 40 years old. Clinical presentation included asymptomatic liver disease (57.1%), neurological disease (20.6%), overt liver disease (12.7%), acute liver failure (6.3%) and other (3.2%). Kayser–Fleischer rings were detected in 27/62 with a higher frequency in neurologic patients (P < 0.001). Ceruloplasmin values were low in 55/63 with significantly lower values in patients with neurological disease (P = 0.048) and in cirrhotic patients (P = 0.017). Increased 24-hour urine copper was measured in 59/63 patients. D-penicillamine was administered in 56/63 patients (88.8%), followed by trientine (6/63, 9.5%), while one patient needed liver transplantation at baseline. At least one treatment switch was performed in 18 patients. By the end of follow-up, all non-cirrhotic patients (25/25) were stable, 3/23 (13%) cirrhotic developed decompensated liver disease, two developed HCC, three received a liver transplant and two died. Five out of 13 neurologic patients had persisting symptoms despite treatment. Conclusion: Wilson disease presents with a wide spectrum of clinical manifestations and should be investigated even in older patients, as early diagnosis, close follow-up and treatment monitoring usually provide favorable outcomes.